{"entity":{"id":"nct05688605","kind":"trial","name":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of MRG003+HX008 in advanced solid tumours, run by Lepu Biopharma Co., Ltd., now recruiting.","summary":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05688605 by Lepu Biopharma Co., Ltd., with 18 participants planned, started 2022-06-30 and due to reach its primary completion in 2027-08. Interventions recorded: MRG003+HX008.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05688605","url":"https://clinicaltrials.gov/study/NCT05688605"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["lepu-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05688605","phase":"1/2","setting":"An Open-label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MRG003 in Combination With HX008 in Patients With EGFR-positive Advanced Solid Tumors","sponsor":"Lepu Biopharma Co., Ltd.","enrolled":18,"outcomes":[]},"route":"/trials/nct05688605/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/"}]}}